Optimizing Immune Checkpoint Inhibitor/Targeted Therapy Combination Adverse Event Management

Get personalized guidance on managing immune-related AEs for your patients with our newly updated Interactive Decision Support Tool adapted from the latest NCCN guidelines. Then, gain multidisciplinary insights into managing toxicities from ICI/targeted therapy combination regimens with an expert text module and downloadable slides.

Share

Program Content

Activities

AEs With ICI/Targeted Tx
Expert Strategies for Managing Adverse Events With Combination Immune Checkpoint Inhibitor/Targeted Therapy
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: May 25, 2023

Expires: May 24, 2024

Activities

AEs With Combo ICI Tx
Managing Adverse Events With Combination Immune Checkpoint Inhibitor/Targeted Therapy
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 19, 2023

Activities

Managing irAEs: NCCN Guidelines® Tool
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Managing Immune Checkpoint Inhibitor–Related Toxicities: An Interactive Decision Support Tool
Tool
Congratulations: You achieved a completion on 04/09/2022

Released: July 18, 2023

Activities

irAE Tool Updates
An Interactive Algorithm Tool Featuring Updated NCCN Guidelines® for Managing Immune-Related Adverse Events
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 17, 2023

Faculty

cover img faculity

Eric Jonasch, MD

Professor, Department of GU Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas

cover img faculity

Kathleen N. Moore, MD, MS

Virginia Kerley Cade Chair in Developmental Therapeutics
Deputy Director
Associate Director Clinical Research
Stephenson Cancer Center at OU Health
Oklahoma City, Oklahoma

cover img faculity

John A. Thompson, MD

Professor of Medicine
Division of Medical Oncology
University of Washington
Seattle, Washington

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca, Eisai, Merck Sharp & Dohme LLC, and Regeneron Pharmaceuticals, Inc.

AstraZeneca

Eisai

Merck Sharp & Dohme, LLC

Regeneron Pharmaceuticals, Inc